Sheta Saad A, Al-Sarheed Maha A, Abdelhalim Ashraf A
Division of Anesthesiology, Department of Oral maxillofacial Surgery & Anesthesia, College of Dentistry, King Saud University, Riyadh, Saudi Arabia.
Paediatr Anaesth. 2014 Feb;24(2):181-9. doi: 10.1111/pan.12287. Epub 2013 Nov 15.
This prospective, randomized, double-blind study was designed to evaluate the use of intranasally administered dexmedetomidine vs intranasal midazolam as a premedication in children undergoing complete dental rehabilitation.
Seventy-two children of American Society of Anesthesiology classification (ASA) physical status (I & II), aged 3-6 years, were randomly assigned to one of two equal groups. Group M received intranasal midazolam (0.2 mg·kg(-1)), and group D received intranasal dexmedetomidine (1 μg·kg(-1)). The patients' sedation status, mask acceptance, and hemodynamic parameters were recorded by an observer until anesthesia induction. Recovery conditions, postoperative pain, and postoperative agitation were also recorded.
The median onset of sedation was significantly shorter in group M 15 (10-25) min than in group D 25 (20-40) min (P = 0.001). Compared with the children in group M, those in group D were significantly more sedated when they were separated from their parents (77.8% vs 44.4%, respectively) (P = 0.002). Satisfactory compliance with mask application was 58.3% in group M vs 80.6% in group D (P = 0.035). The incidences of postoperative agitation and shivering were significantly lower in Group D compared with group M. Thirteen children (36.1%) in group M, showed signs of nasal irritation with teary eyes, and none of these signs was seen in the children in group D (P = 0.000). There were no incidences of bradycardia, hypotension, in either of the groups during study observation.
Intranasal dexmedetomidine (1 μg·kg(-1)) is an effective and safe alternative for premedication in children; it resulted in superior sedation in comparison to 0.2 mg·kg(-1) intranasal midazolam. However, it has relatively prolonged onset of action.
本前瞻性、随机、双盲研究旨在评估经鼻给予右美托咪定与经鼻给予咪达唑仑作为接受全面牙齿修复的儿童术前用药的效果。
72名美国麻醉医师协会(ASA)身体状况分级为I级和II级、年龄在3至6岁的儿童被随机分为两组,每组人数相等。M组接受经鼻咪达唑仑(0.2mg·kg⁻¹),D组接受经鼻右美托咪定(1μg·kg⁻¹)。在麻醉诱导前,由一名观察者记录患者的镇静状态、面罩接受情况和血流动力学参数。还记录了恢复情况、术后疼痛和术后躁动情况。
M组的镇静中位起效时间为15(10 - 25)分钟,明显短于D组的25(20 - 40)分钟(P = 0.001)。与M组儿童相比,D组儿童在与父母分离时镇静程度明显更高(分别为77.8%和44.4%)(P = 0.002)。M组面罩应用的满意依从率为58.3%,而D组为80.6%(P = 0.035)。与M组相比,D组术后躁动和寒战的发生率明显更低。M组有13名儿童(36.1%)出现鼻刺激伴流泪的迹象,而D组儿童未出现这些迹象(P = 0.000)。在研究观察期间,两组均未发生心动过缓、低血压。
经鼻给予右美托咪定(1μg·kg⁻¹)是儿童术前用药的一种有效且安全的替代方法;与0.2mg·kg⁻¹经鼻咪达唑仑相比,它能产生更好的镇静效果。然而,其起效时间相对较长。